Givosiran, developed by Alnylam Pharmaceuticals in Cambridge, Massachusetts, is a highly selective siRNA designed to reduce the occurrence of recurrent episodes in conditions like acute intermittent porphyria (AIP) by downregulating hepatic delta-aminolevulinic acid synthase 1 (ALAS1) enzyme expression [169,170]. Here, ALAS1 is linked to acute intermittent porphyria.